An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma.

Trial Profile

An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Carfilzomib (Primary)
  • Indications Multiple myeloma
  • Focus Biomarker; Registrational; Therapeutic Use
  • Sponsors Amgen; Onyx Pharmaceuticals
  • Most Recent Events

    • 07 Dec 2016 Results of a population pharmacokinetic model analysis and exposure response analysis based on pooled data from PX171-003, PX171-004, PX171-005, PX171-006, PX171-007, ASPIRE, ENDEAVOR, CFZ001 and CFZ002 studies published in the Journal of Clinical Pharmacology.
    • 06 Nov 2012 Data from four phase II trials will be presented at the 54th American Society of Hematology Annual Meeting (abstract #4037), according to an Onyx Pharmaceuticals media release.
    • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top